Veena MN1, Satish KM2*, Rajeev N2 and Sumit M3
1Department of Clinical Pharmacology, KVG Medical College, India 2Department of Anesthesiology and Critical Care, Command Hospital Air Force, India 3Department of Orthopedics, Manyavar Kashiram Combined Hospital and Trauma Center (MKCHTC), IndiaFulltext PDF
Background: HRQOL is a concept that covers a broad range of human experience. In the medical domain it denominates aspects of the health from the patient’s point of view, and is expressed as ‘‘subjective health’’ or ‘‘functional status and wellbeing’’. Aim: To study and confirm the association of various HRQOL indices which are altered due to either of the drugs BBs or CCBs. Material and Method: After institutional ethics committee approval and obtaining written informed consent patients were divided into two groups. Group A BB (n=30) and Group B CCB (n=40). The present study was designed to compare various HRQOL indices which are altered due to BBs vs. CCBs as additional antihypertensive agents in diabetic patients. It was designed as an open-label parallel group comparative clinical study. Results: At baseline, the values for both BB and CCB groups were more than 68 meaning reasonably good quality of life and these values were not statistically different with each other. With 35 weeks of treatment, VAS was increased in CCB group whereas it was decreased in BB group meaning that CCB improved the quality of life perception by patients themselves whereas it was worsened by BB. This difference was statistically significant. After 35 weeks of usage in type 2 DM patients, calcium channel blockers were shown to be associated with significantly lesser perception of pain by the patients in comparison to beta blockers. Conclusion: CCB when added as additional antihypertensive to type 2 DM patients did not alter the patients’ perception in the HRQOL EQ-5D domains of mobility, pain and anxiety/depression.
HRQOL: Health-Related Quality of Life Index; BB: Beta Blockers; CCB: Calcium Channel Blockers
Veena MN, Satish KM, Rajeev N, Sumit M. Health-Related Quality of Life Index in Diabetic Patients: A Comparative Study between Beta Blockers vs. Calcium Channel Blockers. Am J Pharmacol. 2020; 3(1): 1026.